US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
FDA approves GSK vaccine to combat meningococcal infections
Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...
FiercePharma14h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
devdiscourse3h
Health Sector Faces Turbulent Times with FDA Holds, Government Overhauls, and AI Innovations
Recent health news highlights US FDA's hold on Moderna's norovirus vaccine trial due to a side-effect case, Robert F. Kennedy ...
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...
GSK Q3FY25 Results: Net profit jumps 4X to ₹229 crore; revenue improves 18%
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...
STAT22h
U.K. lawmaker wants regulators to probe pharma companies over ‘misleading’ Covid-19 vaccines statements
A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...
Shareholder Rights Law Firm Robbins LLP Reminds GSK Investors With Large Losses To Seek Advice On Leading The GSK PLC Class Action
About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...
Here’s the dividend forecast for GSK shares through to 2026!
City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...
ENDPOINTS NEWS12h
GSK fol­lows Pfiz­er in meningo­coc­cal vac­cine race with new FDA nod
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.